The newborn screening for spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) market is growing as healthcare systems prioritize early detection of rare but serious genetic disorders. The market was valued at USD 2.09 billion in 2024 and is projected to reach USD 3.2 billion by 2032, growing at a CAGR of 5.48%.wiseguyreports

SMA affects motor neurons and can lead to progressive muscle weakness, while SCID severely affects immune-system function and can leave infants highly vulnerable to infections. These conditions may not always be apparent at birth, which makes systematic newborn screening particularly important. Early identification can help clinicians begin confirmatory testing, specialist referral, and appropriate treatment planning before serious complications develop.

Population-based screening is the largest screening-method segment because it aims to ensure that all newborns are evaluated regardless of family history or socioeconomic background. Targeted screening is also relevant for families with a known genetic risk or a history of inherited disease. Blood samples remain the leading specimen type because dried blood spot collection is established within newborn screening programs and can support several types of laboratory testing.wiseguyreports

Molecular genetic testing is the leading technology segment. It is widely used because it can identify genetic changes associated with SMA and SCID. Biochemical testing and tandem mass spectrometry also support the broader screening landscape, particularly as public-health programs expand the number of conditions included in standard newborn panels.

Technological advances are supporting greater accuracy, efficiency, and scale. Next-generation sequencing, multiplex testing, automated laboratory workflows, and point-of-care systems may allow providers to detect multiple conditions using a single sample. These tools are particularly important for countries that want to expand newborn screening while managing laboratory capacity and cost.

Government funding and public-health initiatives are major drivers. National and regional screening programs can improve access by making testing available soon after birth. Awareness campaigns also help parents and healthcare professionals understand the value of early screening and intervention.

North America leads the market because of established newborn screening infrastructure and advanced diagnostic facilities. Europe follows through expanding public-health programs, while Asia-Pacific is expected to grow rapidly as birth rates, diagnostic investment, and healthcare awareness rise. Major companies include PerkinElmer, Bio-Rad Laboratories, Thermo Fisher Scientific, Illumina, Agilent Technologies, Siemens Healthineers, Sarepta Therapeutics, BioMarin Pharmaceutical, and Ionis Pharmaceuticals.wiseguyreports

Read more: Newborn Screening for SMA and SCID Market

People Also Ask

Q1. Why is newborn screening for SMA and SCID important?
Early detection can support timely specialist referral, confirmation of diagnosis, and appropriate treatment planning before serious complications develop.

Q2. Which technology is widely used for SMA and SCID screening?
Molecular genetic testing is widely used because it can identify genetic variants associated with these rare disorders.

Tags: newborn screening, SMA screening, SCID screening, molecular genetic testing, rare disease diagnostics